SMAD2 and breast carcinoma: Pseftogas et al. (57) explored the regulatory effect of CYLD in the hyperplastic alterations in the mammary epithelium of breast cancer, which is associated with the increased nuclear expression of TAZ and phosphorylation of Smad2/3, a key factor in TGF-β pathway, further supporting the involvement of TAZ in TGF-β-facilitated tumorigenesis.